The Epidemiology of Paediatric Brain Cancer — Descriptive Epidemiology and Risk Factors by Ranger, Adrianna
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 26
The Epidemiology of Paediatric Brain Cancer —
Descriptive Epidemiology and Risk Factors
Adrianna Ranger
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/52427
1. Introduction
Cancer  is  the  most  frequently  diagnosed disease-related cause  of  death among children
and adolescents [1]. Of all paediatric cancers, those involving the central nervous system
(CNS), and especially the brain, are collectively among the most common, ranking as the
most common solid tumor and either first  or second overall  (second only to leukaemia)
in the United States (USA) [1]- [5], Canada [6], and Mexico [7]. For example, in the USA
in 2004, 555 cases of CNS cancer-related death were confirmed among children, and 566
for leukemia, representing 25.0% and 25.5%, and therefore accounting, between them, for
more than half of the total number of cancer deaths in individuals under age 20 [1]. Sim‐
ilar numbers through 2011 are published in an on-line report of the National Cancer In‐
stitute [5]. Since in excess of 90% of primary CNS cancers in children originate within the
brain [4], from this point onward, this chapter will generally be limited to primary brain
cancers. The American Brain Tumor Association  has claimed that approximately 4,200 chil‐
dren  younger  than  age  20  will  be  diagnosed  with  a  primary  brain  tumor  in  the  year
2012, of whom 3,020 will be under the age of 15 [8].
Survival rates from brain cancer have improved dramatically over the past forty years,
presumably due to a combination of improved treatments and earlier detection [9]. However,
there are concerns that the incidence of brain cancer has increased and/or is destined to increase
due to the emergence of a host of new risk factors with almost universal exposure, especially
in industrialized countries. Among these novel risk factors is the exponentially increasing use
of hand-held electronic devices like cell phones, iPods, iPads and other electronic reading
devices [10]- [12].
But is the incidence of brain cancer really increasing? Is this increase universal or just in certain
countries and regions? Are these new devices playing a role? This chapter reviews the
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descriptive epidemiology of brain cancer in the paediatric age group, specifically looking at
trends over time, followed by an examination of known and suspected risk factors. The first
question is: Is the incidence of brain cancer really increasing?
2. Descriptive epidemiology
2.1. The incidence of paediatric brain cancer: Trends over time
Before discussing its incidence, it is necessary first to define what is meant by paediatric brain
cancer. For the purposes of this chapter, only primary cancers of the brain will be considered,
excluding metastases to brain from other sources, like lung and breast. Brain tumors are quite
heterogeneous, in terms of both their histology and clinical course and prognosis. There also
are exceedingly rare forms that stem from highly specialized cells, in addition to types that are
more common. Most research on brain cancer has focused on the most common, which also
tend to be the most lethal forms.
Cancers involving neurons themselves are quite rare, the majority of brain cancers involving
cells that originate within the glial cell line [4]. Such glial cell cancers include astrocytomas in
all their different forms and grades, from pilocytic astrocytomas to glioblastoma multiforme;
oligodendrogliomas; other gliomas, and ependymomas. Primitive neuroectodermal tumors
(PNET), which arise from primitive neuroectodermal tissues and include medulloblastomas,
are another relatively common brain neoplasm that tends to arise in very young children;
PNET account for approximately 20% of malignant CNS tumors in children [4]. Together,
astrocytomas, oligodendrogliomas and other gliomas, ependymomas, and PNETs account for
roughly 97% of all malignant paediatric brain tumors [4]. All remaining brain tumors are either
very rare, usually benign, or both; and they all are especially uncommon in children. Primary
CNS lymphomas that arise from the cells and tissues that comprise the CNS lymphatic system
comprise one to two percent of all primary brain tumors, with patients whose immunity is
compromised (e.g., AIDS patients and organ transplant recipients) at especially high risk.
Other brain tumors that can be malignant but are usually benign include meningiomas, that
are quite common, and pituitary and pineal tumors, which are much rarer, especially in
children and adolescents. In this chapter, all brain cancers will be discussed; but the majority
of research that has been conducted on risk factors for brain cancer in children has involved
astrocytomas, oligodendrogliomas and other gliomas, ependymomas, and PNETs [4].
Despite  its  obvious  importance  as  a  medical  issue,  publications  on  general  population
studies (as opposed to case-control studies) assessing brain cancer incidence trends over
time, and especially on its incidence in children, have been surprisingly rare. Almost all
published  general  population  data  are  at  least  a  decade  old,  harkening  back  to  a  time
when there  was  considerable  concern that  the  incidence  of  brain  cancer  was  increasing
[4], [13]- [17]. Exceptions are longitudinal studies in the United Kingdom [18] and in In‐
dia [19]. In the USA, between 1973 and 2001, the overall age-adjusted incidence of brain
cancers  was  6.1  cases  per  100,000  person-years,  of  which  roughly  46%  (2.8  cases  per
100,000 person-years)  were the most  malignant  form,  glioblastoma multiforme [13].  The
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incidence  in  children  was  2.5  per  100,000  person-years.  Overall,  brain  cancer  rates  in‐
creased steadily between 1973 and 1987, but then declined steadily afterwards; however,
across  all  ages,  the  incidence  of  glioblastoma  in  2001  was  greater  than  the  mean  inci‐
dence  over  the  28  years  of  observation  (3.0  versus  2.8  per  100,000).  Though  mortality
across all brain cancers declined over the study period, survival did not improve for glio‐
blastomas [13]. Data specifically on US children under age 15 between 1975 and 1995 re‐
veal a clear increase in brain cancer incidence throughout the study period, rising from a
low of under 2.5 per 100,000 person-years in 1975 and 1976 to highs of roughly 3.2 per
100,000  in  1987  and  1993  [4].  Further  analysis  of  this  trend  identified,  rather  than  a
steady increase, a marked ‘jump’ in rate between the periods before and after 1985 [20],
which corresponds to the marked increase in the availability of magnetic resonance imag‐
ing (MRI) for brain cancer detection in the mid 1980s and consistent with the lack of any
significant  increase  in  brain  cancer  mortality  rate  [4].  Interestingly,  the  noted  increase
was site specific,  with incidence more than doubling in the brainstem and increasing by
more than 50% in the cerebrum, but actually declining in the cerebellum and increasing
by a mere 6% across all other sites [20]. Similarly, in the Northeastern U.S., certain brain
cancers  were  noted  to  increase  in  incidence  between  1954  and  1998  more  than  others,
with annual  increases of  1% in pilocytic  astrocytomas,  1% in primitive neuroectodermal
tumors, and 2.3% in miscellaneous gliomas [21].
The Surveillance Epidemiology and End Results database initially was created by the U.S. National
Cancer Institute (NCI) in 1973 as the coalescence of 9 regional cancer registries to generate
epidemiological data on cancer in the U.S. [22] It has since expanded to collect data on a broad
array of cancers from registries representing 26% of the total U.S. population, and data on
specific cancers are available for 1975 through 2009, including brain and other nervous system
cancers [23]. SEER data demonstrate an overall incidence of brain and other nervous system
cancers (invasive) of 5.85 across both sexes and all ages and races in 1975, with subsequent
peak incidences of 6.51 in 1981, 7.05 in 1990, and 6.91 in 1999, with a gradual decline afterwards
to 6.58 in 2009, for an overall incidence over the 35 years of data collection of 6.60 per 100,000
[24], and an average of 6.50 over the five years 2005 through 2009 [25]. Data by age are currently
only listed for 2005 through 2009, and average 3.1 per 100,000 for those 19 and under, versus
19.6 for those 65 and older [25].
In other countries over roughly the same time period, roughly a 25% increase in cancer
incidence was noted in Austria between 1970 and 2002, with mortality from brain cancer
peaking in 2002 [14]; in Brazil between 1980 and 1998, age-adjusted brain cancer mortality rates
across all age groups increased by approximately 50% (from 2.24 to 3.35 105) [16]; in Norway
between 1970 and 1999, the overall rate of brain and CNS tumors increased from 6.49 to 12.02
cases per 100,000 person-years, an 85% increase, with a trend of continuing increase from
1995-1999, especially in children 0-4 years old and in those 60 years and older [17]; and in India
between 1982 and 2003, statistically-significant 3.1 to 4.7% increases in incidence were noted
at three of five major centres (Mumbai, Bangalore and Chennai) for both males and females
across all ages, while incidence remained stable in Delhi and Bhopal [19]. Over a somewhat
earlier period, incidence and mortality from brain cancer rose significantly in Canada between
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1959 and 1987, though this was most marked in elderly males [26], and incidence doubled
between 1948 and 1988 in New Zealand [27].
Contrary to these increases, in the United Kingdom between 1998 and 2007, no significant time
trends were noted in overall incidence of brain cancers for either gender, or for any specific
age group [18]. Site-specific increases were noted for the temporal lobe in men (0.04 new cases
per year) and women (0.02 per year), accompanied by decreases in the rates of cancers
involving the parietal lobe (-0.03 per year), cerebrum (-0.02 per year) and cerebellum (-0.01 per
year), but in men only. The authors conjectured that the observed increase in the rate of
temporal lobe cancers, if caused by mobile phone use, would constitute less than one additional
case per 100,000 people over the observation period.
Consequently, though clear increases in the incidence of brain cancer were evident interna‐
tionally into the 1990s, since that time there appears to have been relative stabilization, at least
in the U.S and the U.K. Unfortunately, a lack of readily-accessible international data over the
past decade precludes any assumptions beyond these two countries.
2.2. Trends in mortality from brain cancer
Brain cancer is the second leading disease-related (non-traumatic) cause of death among
children and adolescents, behind leukemia, generally accounting for between 500 and 600
deaths per year in the USA since the year 2000 [1], [5]. However, in contrast with trends towards
increasing incidence in many populations, overall there has been a decline in mortality from
brain neoplasms over the past three to four decades, and this decline has been relatively
continuous, even over periods of time when incidence has appeared to rise [4], [13], [20], [28].
In the U.S., this trend has been especially evident in children [4], [13], [20], [28], [29], with five-
year relative survival rates from all brain cancers rising in those under age 15 from 59% between
1975 and 1984 to 67% between 1985 and 1994 [4] to over 70% by 2012 [30]. In terms of absolute
numbers, mortality rates from brain malignancies declined from 1.0 per 10 [5] children in the
1970s, to 0.8 per 100,000 children in the 1990s, and then to roughly 0.6 per 100,000 from 2005
through 2009 in the SEER database [25].
Improvements in survival have been observed with certain neoplastic types much more than
others, with survival rates from ependymomas increasing from 39 to 56% and from gliomas
from 46 to 57% between these two time intervals. Overall improvements in survival generally
have not extended to PNETs/medulloblastomas, with survival increasing only 3%, from 52 to
55% between 1975 and 1994 [4]. Nor have significant improvements been noted with glioblas‐
tomas [13], for which 1-year and 5-year survival rates have consistently fallen below thirty-
five and five percent, respectively [4], [13], [31], [32]. Fortunately, as previously stated, children
are much more likely than adults to have low-grade astrocytomas, in particular pilocytic
astrocytomas and other low-grade gliomas that are almost never fatal and often cured,
depending upon their location and surgical accessibility [33]- [35]. They also are far less likely
to have virtually universally-fatal glioblastomas than adults, in whom they are the most
common brain tumor type [8], [35]. Diffuse pontine gliomas, which account for roughly 15%
of paediatric brain malignancies and arise anytime from infancy through adolescence, peaking
in those between the ages of 7 and 9 years old, have a universally dismal prognosis, with
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median survival times of 12 months or less, irrespective of tumor grade; this is because their
diffuse nature renders them unresectable [3] [6], and they tend to be unresponsive to either
radiation or chemotherapy [37], [38].
At all ages, pediatric brain cancer survival rates have typically been much better than for adults
[4], [13], a fact that largely can be explained by the much higher percentage of low-grade
astrocytomas and gliomas, and much lower percentage of high-grade astrocytomas seen in
children [8], [35]. Even among pediatric patients, however, survival rates vary with age, with
older adolescents (ages 15 to 19) generally having fared better than children under age five, in
whom low survival rates are especially noted for ependymomas and PNETs. This has been
true not only in terms of current rates of survival (between 1986 and 1994, overall survival
from all brain cancers was 77% in those 15 to 19 years old, versus just 45% in those under one
year of age, and 59% in those between 1 and 4 years old), but also in terms of improvement in
survival over time [4].
It  must  be  considered,  however,  that  long-term  survival  in  children  with  brain  cancer
does not necessarily equal ‘cure’, and that low-grade neoplasms are not necessarily cura‐
ble.  How children do long-term is  largely dependent  upon the location and size  of  the
tumor,  its  surgical  accessibility,  and  its  potential  for  re-growth  [33],  [34].  For  example,
even low-grade optic gliomas, localized brainstem gliomas, and medulloblastomas might
never be cured, merely because of their location and associated high risks of surgical in‐
tervention. Moreover, even with lesions for which curative surgery is successful,  consid‐
erable  post-operative  morbidity  can result  secondary to  neurological  damage caused by
the tumor,  especially  if  fast  growing,  and to the surgery itself  [33],  [34],  [39].  Radiation
therapy,  classically used to de-bulk brain tumors prior  to attempted resection,  has been
virtually contra-indicated in infants and preschool children, because of the adverse effects
of radiation on the developing brain.
3. Known risk factors
3.1. Demographic variables (age, gender, and race)
Though relatively few data exist specifically addressing the association between various
demographic factors and childhood brain cancers, the overall relationship between brain
cancer incidence and mortality and patient age, gender and race have been well-established
via a number of published studies [4], [13]- [19], [26]- [28], [40]- [42], as well as the SEER
database [22]- [25]. In those under age twenty, age predicts not only overall incidence of and
mortality from brain cancer, but also the incidence of and rate of survival from specific cancer
types, and the risk of cancer at specific brain locations. From 2005 through 2009, the overall
incidence of brain and other nervous system cancers was 3.7 per 100,000 in infants under one
year of age, peaked to 3.9 in those 1 to 4 years old, and then steadily declined to 2.1 per 100,000
in adolescents between 15 and 19 [13], [25]. These numbers parallel earlier figures for 1986
through 1994, when incidence was 3.6 per 100,000 in infants, peaked to almost 4.0 by age 4,
and then steadily declined to under 1.7 per 100,000 by age 19 [4]. In terms of lesion location,
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cerebellar lesions were much more common in children nine years old and under, at 0.93 and
0.97 per 100,000 for those under 5 and 5-9 years old, respectively, than in older children, being
just 0.37 per 100,000 in children over 15 [4]. Similar patterns were evident for brain stem lesions
and brain sites other than the brainstem, cerebellum and cerebrum [4]. Cerebral lesions,
however, predominated among those over age 10 (see Figure 1).
Figure 1.
Age also influences the types of brain cancer seen, especially in terms of ependymomas, most
of which initially present in children under five years of age; and PNET, the incidence of which
decreases steadily with age, from over 1.1 per 100,000 in the first year of life to roughly 0.2 per
100,000 in older teens [4]. The relatively poor prognosis of ependymomas and PNET, relative
to the often low-grade gliomas and astrocytomas of childhood and adolescence, result in
higher mortality rates among those under age five in both the U.S. and the U.K. [4], [41]; but
other studies have also noted lower survival rates in younger versus older children with the
same tumor; for example, low-grade astrocytomas [43] and ependymomas [41], [44].
Being male is considered a moderate risk factor for brain cancer. In the SEER database, over
the entire period from 1975 through 2009, the incidence of CNS cancers was 7.90 per 100,000
in males versus 5.55 per 100,000 in females, and this disparity between the two sexes was
evident every year, the rates being 7.72 and 5.60 per 100,000 in 2009 [24]. Over the entire time
period, the incidence in males averaged 42% higher than in females, and this was relatively
consistent. Similar population-based excess in brain cancers among males have been reported
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in Canada [26], the U.K. [18], Norway [17], Austria [14], India [19], New Zealand [27], and in
69 populations from a subset of cancer registries included in the Cancer Incidence in Five
Continents database, in which male/female incidence rate ratios varied by age, but not by World
Area, suggesting that the observed male versus female difference in brain cancer incidence is
biologically based [45]. At least in the U.S. among children, this gender discrepancy largely is
secondary to male predominance in certain neoplasms more than others, especially in
medulloblastomas and ependymomas [4]. To date, however, no clear association between
gender and cancer mortality rates has been established, especially among children.
Another very clear demographic predictor of brain cancer incidence, mortality, and type is
race. Using the SEER database, between 1975 and 2009, whereas the overall incidence of brain
and other nervous system cancers was 7.18 per 100,000 in whites, it was just 4.08 per 100,000
in blacks [24], 43% lower. This discrepancy between the races persists over the most recent 5-
year data block from 2005-2009, in which the rates were 7.1 and 4.0 per 100,000 (44% lower),
respectively [25]. A similar difference is observed for mortality, with mortality rates among
whites and blacks being 4.6 and 2.5 per 100,000 over the same 2005-2009 time period, making
mortality from brain cancer 46% lower in blacks. The incidence of astrocytic glioma and
medulloblastoma are particularly more prevalent in whites than blacks [46]. A similar low rate
of brain cancer and brain cancer mortality, relative to Caucasians, has been identified for
Hispanics and Asians. In California, for example, in data gleaned from the State Cancer
Registry for 1988-1997, the odds of CNS cancer was 0.70 among blacks (i.e., 70% of the rate
among whites), 0.64 among Asians, and 0.57 among Hispanics relative to Whites. [42] Not all
non-Caucasian populations are protected, however. In New Zealand, at least as of 1988, the
native Maori population exhibited a fourfold increase in their incidence of ependymomas
versus Caucasians, as well as a significant overall increase in all brain cancers [27].
3.2. Family history of cancer or other CNS disease
As will be discussed in the next section, there is a clear association between certain familial
syndromes and brain malignancy. Even beyond this, however, studies support an association
between family history and brain cancer, albeit less conclusive than for age, sex and race, and
generally for brain cancers in general and not just pediatric brain cancers. For example, Farwell
and Flannery compared the occurrence of cancer in parents, siblings, and offspring of 643
patients who had had a CNS tumor in childhood, as recorded in the Connecticut Tumor
Registry, with its occurrence among the parents, siblings, and offspring of 360 controls
matched for sex, birth date, and birthplace [47]. Overall cancer incidence was comparable in
the two groups, but 11 CNS tumors were identified in the relatives of cases, versus none in the
relatives of controls (p = 0.0005). The rate hematopoietic-lymphatic system tumors also was
increased (p = 0.003). In addition, nine siblings of cases but only one sibling of a control had
had cancer as a child. Medulloblastoma and glioblastoma multiforme were overrepresented
in the group of children whose relatives had CNS tumors. Overall, a fivefold increase in CNS
or hematopoietic-lymphatic malignancies was identified in cases versus controls.
In another study in which the nationwide Swedish Family-Cancer Database for the years 1958
through 1996 was used to analyze the risk of brain tumors in offspring ages 15-61 and siblings
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via parental cancer probands, among brain tumor patients, standardized incidence ratios (SIR)
were statistically elevated to 1.7, 2.4, and 2.5 for all brain tumors, astrocytomas, and meningi‐
omas, respectively. In addition, parental endometrial cancer and melanoma were associated
with offspring astrocytoma, and parental breast and thyroid cancers with offspring ependy‐
moma and neurinoma, respectively [48]. In a case-control study in Maryland, subjects with a
family history of stomach cancer (odds ratio, OR, 2.2; 95% CI, 1.0-4.6), colon cancer (1.4; 0.9-2.2),
prostate cancer (2.1; 1.1-3.8) or Hodgkin’s disease (2.4; 0.9-6.3) all had an increased odds of
glioma [49], while increased risk of meningioma was noted among those reporting a family
history of benign brain tumor (4.5; 1.0-21.0) or melanoma (4.2; 1.2-15.0), and a family history
of breast cancer was associated with an elevated meningioma risk among subjects 18 to 49
years old, but not older (3.9; 1.4-11.0) [50].
More recently, using the Utah Population Data Base (UPDB), among first degree relatives of
a proband with brain cancer, the relative risk (RR) was found to be almost 4 (3.8) for astrocy‐
tomas, 2.3 for glioblastomas, and 3.3 for both, each of these RR values statistically greater than
1.0; among second degree relatives, only astrocytomas had a relative risk greater than 1.0 (RR
= 1.9) [51]. Finally, in the Ohio Brain Tumor Study (OBTS), Ostrom et al. identified a significant
association between a family brain cancer history and both malignant (e.g., malignant gliomas)
and benign brain tumor subtypes, like meningiomas, acoustic neuromas, and pituitary
adenomas [52]. Overall, the increased risk of brain cancer if a parent or sibling has had brain
cancer has been estimated to be between 3 and 9-fold [4].
Some data also exist that support an association between brain cancer and a family history of
epilepsy [53], [54], and between brain cancer and a family history of mental retardation [53],
though these data are less conclusive. For example, in the 1991-1995 San Francisco Bay Area
Adult Glioma Study, in which both personal and family histories were examined in 462 adults
newly-diagnosed with glioma versus 443 controls, past epilepsy or seizures only were
identified as a personal risk factor, the only family history risk factor identified being brain
cancer, and only when both confirmed and probable family brain cancer cases were considered
(OR 2.3; 95% confidence interval 1.0-5.8) [55]. Cancer in general, and a host of other health
conditions were not significant predictors of glioma cases, either in personal or family history.
3.3. Genetics
Central nervous system cancers occur within a broad range of familial clinical syndromes
including what some consider the prototype CNS tumor syndromes – neurofibromatosis,
types I and II - but also other skin conditions that, along with neurofibromatosis, are collec‐
tively known as the phakomatoses. These additional syndromes include disorders like tuberous
sclerosis, Von Hippel Lindau Disease, and basal cell nevus syndrome. Other familial disorders
have been clearly linked to increased CNS cancer risk as well, like Li-Fraumeni syndrome, a
congenital condition linked to germ-line mutations of the p53 tumor suppressor gene, and
familial polyposis disorders, like Turcot syndrome. Finally, this author has already published
several papers describing the association between CNS tumors and dyschondroplasia
syndromes, in particular Ollier’s disease and Maffucci’s syndrome. A list of this broad array
of genetic familial syndromes associated with increased CNS tumor risk is provided below.
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• Phakomatosis syndromes
• Neurofibromatosis (types 1 and 2, and segmental forms)
• Tuberous sclerosis
• Von Hippel Lindau disease
• Basal cell nevus syndrome
• Other familial syndromes
• Li Fraumeni syndrome
• Familial polyposis syndromes (e.g., Turcot syndrome)
• Rubenstein-Taybi syndrome
• Dyschondroplasia syndromes
Ollier’s disease
Maffucci’s syndrome
Table 1. Familial Syndromes Associated with CNS Malignancies
4. Neurofibromatosis and other phakomatosis syndromes
The phakomatoses are characterized by the presence of pathological lesions involving the skin,
eyes and central and peripheral nervous system (CNS) [56], all tissues of ectodermal origin.
The phakamotoses otherwise share the features of being autosomal dominant, with variable
expression but high penetrance; and all involving mutations of a tumor suppressor gene.
Initially conceptualized by the ophthalmologist van der Hoeve in the early nineteenth century
[57], they were assumed to primarily consist of three disorders: neurofibromatosis, tuberous
sclerosis, and what we now know as von Hippel-Lindau syndrome. Over time, each of these
three disease labels has been recognized as a collective term for multiple disorders; for
example, neurofibromatosis is not one disease, but a collection of quite distinct diseases. On
occasion, two distinct phakomatosis syndromes (for example, neurofibromatosis and tuberous
sclerosis) have been described in the same patient [58]; but this is rare and may be the result
of chance rather than some increased risk for both conditions. In terms of the current chapter,
these three disorders, as well as more-recently described phakomatoses, share the property of
being associated with an increased risk of malignancies involving the central and, sometimes,
peripheral nervous system.
Neurofibromatosis (NF), which is now recognized not to be one, but at least two distinct
disorders - neurofibromatosis type 1 (NF-1) and neurofibromatosis type 2 (NF-2) [59] - is
the most common of all the phakomatosis syndromes, having been initially described by
Frederick von Recklinghausen in the year 1882 [60]. Each of these two syndromes has its
own diagnostic  criteria  that  are  very  different;  and  whereas  the  characteristic  lesion  in
NF-1 is the neurofibroma, the characteristic lesion in NF-2 is a peripheral nerve Schwan‐
noma or neurolemoma [59], [61]- [63].
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Neurofibromatosis type 1 (NF-1) is the most common form of disease, affecting one in roughly
2500 to 5000 live births [64]- [66]. This renders it more than ten times more common than NF-2
[64], [65]. Though autosomal dominant, up to 50% of cases arise spontaneously from a gene
mutation that occurs on chromosome 17q11.2, which encodes for a large protein called
neurofibromin [64], [66]. This NF-1 gene is a classical tumor suppressor gene, with tumor growth
requiring the loss of BOTH alleles. Neurofibromatosis type 1 has a classical combination of
clinical signs [67], for which the mnemonic CHANSOR has been used. These signs include
Café au lait macules; Hamartomas of the iris (called Lisch nodules); Axillary and Inguinal
Freckling; Neurofibromas; Skeletal lesions – like sphenoid wing dysplasia and thinning of long
bone cortices; Optic gliomas; and in increased Risk of other CNS and systemic tumors. The
disorder is diagnosed using National Institutes of Health (NIH) Consensus Criteria for the
Diagnosis of NF-1 [65]. Besides the classic neurofibroma - which is generally an extra-cranial
lesion that occurs both in paraspinal areas and in peripheral nerves [62], [67], [68] and, though
benign, may transform into a neurofibrosarcoma - numerous other brain tumors are frequently
observed in patients with NF-1. Most common are optic-hypothalamic gliomas, which
manifest in roughly 15% of NF-1 patients. These lesions are categorized into those that involve
just the optic nerve(s), lesions also involving the optic chiasm, and lesions that extend all the
way into the hypothalamus. [69] Hemispheric and cerebellar gliomas are less common than
lesions involving the optic tract [70]. Most are benign or only exhibit low-grade malignant
potential; but all grades of malignancy have been reported [70]. Most are resectable. Brainstem
gliomas also occur, as a heterogeneous group of lesions, with at least three main subtypes: (1)
a diffuse area of brainstem enlargement; (2) focal enhancing nodules with or without cystic
areas; and (3) peri-aqueductal gliomas. All subtypes generally have a very indolent course that
usually does not require treatment, though MRI monitoring is indicated until their indolent
course is confirmed. Some lesions regress on their own [70]. Though controversial, diffuse
brainstem enlargement is presumed to represent gliomatous change, though these lesions have
a more indolent course than brainstem gliomas seen outside of NF-1, such that adjuvant
treatment only is required in that minority of patients whose lesions progress. This being said,
these gliomas occasionally do progress to more malignant forms of astrocytoma, including
glioblastoma [70], [71]. The focal enhancing nodules, with or without cystic areas, generally
are thought to represent pilocytic astrocytomas, given their imaging characteristics. Like
pilocytic astrocytomas elsewhere, they generally are indolent; but their course is unpredictable
and the brainstem so susceptible to major deficits, relative to the cerebral hemispheres, that
ongoing monitoring is required. Small, focal intrinsic lesions may enlarge and then regress
spontaneously. Exophytic tumors often are more aggressive and require treatment.
Finally, peri-aqueductal gliomas occur adjacent to the aqueduct of Sylvius between the 3rd and
4th ventricles in the midbrain. They typically manifest with late-onset aqueductal stenosis,
leading to hydrocephalus. Presumably, they represent low-grade gliomas or glial hamartomas,
and typically are indolent. However, because of their location, shunting often is necessary.
Resection is usually not necessary for any of the brainstem gliomas seen in NF-1 [70], [71].
Neurofibromatosis type 2 (NF-2) is much less common than NF-1, with a prevalence that has
been estimated as roughly one in 25,000 to 50,000 [64], [65], [67]. NF-2 is caused by a mutation
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affecting chromosome 22q12 and the gene product merlin (a moesin-, erzin-, and radixin-like
protein), which sometimes is called schwannomin. Merlin encodes for a polypeptide that may
affect cell growth and motility; more interesting, in terms of its presence in NF-2, is that it is a
tumor inhibitor that often is absent in brain tumors [72]- [74]. In addition, the same chromo‐
somal abnormality is found in spontaneous spinal schwannomas, which suggests that a single
location causes Schwann cell tumor growth [75]. Clinically, NF-2 is a combination of features
that always entails at least one eighth cranial nerve (CN-VIII) neurilemoma, in addition to a
variety of other tumors (e.g., neurofibromas, meningiomas, gliomas, neurilemomas), juvenile
posterior sub-capsular cataracts, and occasional other lesions like café au lait spots. Like NF-1,
it is diagnosed using NIH Consensus Criteria, initially proposed in 1988 [76], but modified in
1997 [77]. Cranial nerve neurolemomas, especially of the eighth cranial nerve (CN-VIII), are
the hallmark lesion of NF-2, with CN-VIII lesions present in roughly 95% of patients with NF-2;
when bilateral, they are diagnostic of NF-2 [63], [67]. As a rule, spinal lesions are more common
in NF-2 than in NF1, while brain lesions are less common in NF-2 than NF-1. In NF-2, this
includes extracranial neurilemomas and meningiomas. But also among the various tumors are
brain neoplasms, particularly ependymomas that are the most common malignancy in NF-2,
versus astrocytomas in NF-1 [62], [63], [70]. These ependymomas usually are well-circumscri‐
bed, and therefore often quite resectable. Their surgical and post-operative management (like
the use of adjuvant therapy) is the same as for intramedullary spinal tumors in patients without
neurofibromatosis.
Tuberous sclerosis, which also is called tuberous sclerosis complex (TSC) and Bourneville’s
disease, is the second most common phakomatosis syndrome, after neurofibromatosis type 1.
It affects anywhere from one in 6000 to one in 30,000 people [78]- [80], with marked variations
in penetrance rendering all estimates somewhat unreliable. The syndrome is autosomal
dominant, but up to 60% of cases arise from spontaneous mutations [78], [80], [81]. Two tumor-
suppressor genes, TSC-1 (tuberous sclerosis complex-1) and TSC-2, are responsible for TS.
Roughly 80-90% of mutations involve TSC-2, while just 10-20% of mutations involve TSC-1
[81]. The genetic locus for TSC-1 is chromosome 9q34, and the TSC-1 gene product is called
hamartin. The genetic locus for TSC-2 is chromosome 16p13.3, and the TSC-2 gene product is
called tuberin. Both hamartin and tuberin appear to have roles in cell differentiation, prolifer‐
ation and migration. The disorder effects cellular differentiation, proliferation and migration
during early development, leading to various diffuse hamartomas and neoplastic lesions that
can affect virtually any body organ [81], [82]. It can present at any age, but most commonly
appears during childhood, especially late childhood. Though skin, heart, lung and renal
involvement are common, neurological involvement is the most common cause of morbidity
and mortality from TS, and the most common cause of death in patients under 30 years old.
Problems stem from a broad variety of intra-cerebral tumors, which include cortical tubers,
subependymal nodules, and subependymal giant cell astrocytomas (SEGA). Subependymal
giant cell astrocytomas develop in between 5 and 15% of TS patients [83], typically developing
in the region of the foramen of Monro, where they frequently cause obstructive hydrocephalus.
Though they are slow-growing and rarely undergo malignant transformation, these tumors
are problematic because of their location and relative inaccessibility for resection. Death
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primarily results from intractable seizures or SEGA-induced obstructive hydrocephalus; and,
overall, the long-term prognosis is poor.
The average age at first presentation with Von Hippel-Lindau Disease is 26 years, and the
average age at diagnosis 31 [84]. Nonetheless, pediatric cases are not uncommon. Von Hippel-
Lindau disease is autosomal dominant, with 97-99% of cases familial and only 1-3% occurring
as a result of spontaneous mutations. It is associated with inactivation of the tumor-suppressor
gene VHL (Von Hippel Lindau), which is found on chromosome 3p25 [84], [85]. Decreased
levels of the VHL protein, which is important in a critical pathway helping cells to adapt to
hypoxic stress, lead to over-expression of a hypoxia-inducible transcription factor (HIF-1)
which, in turn, results in increased cell proliferation, and the over-expression of several growth
factors, ultimately manifesting as multiple, multi-systemic benign and malignant tumors,
which sometimes are bilateral (e.g., both eyes) [86]. These tumors include haemangioblastomas
of the cerebellum, spine, brainstem and retina (the most common tumor identified); renal clear
cell carcinomas; pheochromocytomas; pancreatic and renal cysts; endolymphatic sac tumors
(ELSTs, of the petrous bone at the cerebellopontine angle) [87]; papillary cystadenomas of the
epididymus or broad ligament; and haemanigiomas of the adrenal glands, liver and lungs. As
with all the other phakomatosis syndromes, the diagnosis is made on clinical grounds using
established, published criteria. Central nervous system manifestations are highly prevalent
[88], [89], with CNS haemangioblastomas occurring in 60 to 80% of patients. Moreover, they
are more likely to be multiple and present at an earlier age than when they occur sporadically,
being a presenting feature in roughly 60% of VHL patients [90]. These lesions may occur
anywhere along the cranioaxial axis, but only 1% of these tumors are supratentorial [90]. The
site of lesion determines the symptoms with which the patient presents. The cerebellum and
brainstem are the most common sites of haemangioblastomas in VHL syndrome [90], where
patients present with headaches, vomiting, lethargy, dysmetria, ataxia, papilloedema,
polycythemia from tumor production of erythropoietin, and/or enlarging cysts that may cause
brainstem compression (solid tumors generally do not cause such compression in VHL
syndrome).
As with almost all the phakomatoses, basal cell nevus syndrome (BCNS) is autosomal
dominant, the offending gene, called PTCH1, localized to chromosome 9q31 in about 85% of
cases. The PTCH1 gene product is a trans-membrane receptor that binds to and regulates a
protein called Sonic the hedgehog homolog (SHH), one of three proteins in the mammalian
signalling pathway family called ‘hedgehog’, and one which plays a key role in the regulation
of organ development in vertebrates, including the growth of fingers and toes and the
organization of the central nervous system. It also controls cell division in adult stem cells and
has been implicated in oncogenesis. Mutations in the PTCH1 gene result in uncontrolled SHH
activation [91]. This rare condition, which affects roughly one in 50 to 60 thousand live births
[84], is characterized by multiple basal cell cancers, often presenting in adolescence. Despite
the relatively innocuous-sounding name, there is a wide range of non-neurological manifes‐
tations, including numerous other benign and malignant tumors, both non-CNS and CNS,
including melanomas, leukaemia, lymphoma, lung and breast cancers, medulloblastomas, and
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meningiomas [92]. Like virtually all the familial cancer syndromes, basal cell nevus syndrome
is diagnosed using diagnostic criteria.
5. Other familial syndromes associated with CNS malignancies
Other familial syndromes associated with paediatric CNS malignancies include Li-Fraumeni
Syndrome (LFS), a very rare autosomal dominant disease that is caused by a germ line
mutation of chromosome p53 in roughly 70% of families in which the syndrome is diagnosed
[93]. Patients exhibit a variety of carcinomas and sarcomas, including premenopausal breast
cancers, osteosarcomas, soft tissue sarcomas, acute leukaemia, cancer involving the adrenal
cortex, and primitive neuroectodermal tumors (PNET) like medulloblastoma. This increased
risk of several malignancies likely stems from deactivation of p53, which normally controls
apoptosis and the repair of damaged DNA. Patients present not only with a variety of cancers,
but with cancers at a very early age, with the mean age at presentation of brain tumors being
25 years. The diagnosis of so-called ‘classic LFS’ is made in any patient under 45 years who
presents with a bone or soft-tissue sarcoma, plus one first-degree relative who presents with
any cancer before age 45, plus one further first or second-degree relative of the same lineage
who has had any cancer before age 45 or a sarcoma at any age [94]. More recently, a related
syndrome, called Li-Fraumeni-like syndrome, has been described, defined as a proband with
any childhood tumor or any sarcoma, brain or adrenocortical tumor before 45 years of age,
who has a first- or second-degree relative with any cancer before the age of 60 [95], [96].
Interestingly, whereas p53 germ-line mutations are found in 70% to 80% of families with classic
Li-Fraumeni syndrome, they only are identified in between 20% and 40% of families with Li-
Fraumeni-like syndrome [8] [4]. The CHK2 checkpoint homolog gene, CHEK2, which is located
on the long (q) arm of chromosome 22, also has been implicated in some families with classic
Li-Fraumeni syndrome. Recently, mutation of another gene, which encodes for the breast
cancer 2 (BRCA2) susceptibility protein, has been found with increased frequency in the non-
classic syndrome [96]. It should be noted that p53 mutations are rare in sporadically occurring
medulloblastomas. Overall, about 10% of LFS patients will develop a glioma before the age of
45, and another 5% a supratentorial primitive neuroectodermal tumor (PNET), like a medul‐
loblastoma, or choroid plexus carcinoma [97].
A Canadian surgeon named Jacques Turcot is accredited with having characterized Tur‐
cot  syndrome,  one of  the  several  familial  polyposis  syndromes associated with familial,
in this case autosomal recessive, inheritance and the presence of multiple colonic adeno‐
mas and adenocarcinomas [98].  An additional feature of Turcot syndrome is its  associa‐
tion  with  several  different  neuroepithelial  tumors  of  the  central  nervous  system,
including astrocytomas, medulloblastomas, pineoblastomas, gangliogliomas, and ependy‐
momas [84]. Turcot syndrome has been categorized into types 1 and 2, with type 1 char‐
acterized by glioblastoma, no familial  adenomatous polyposis,  but often hereditary non-
polyposis-related  colorectal  carcinoma.  Germ-line  mutations  in  a  few  DNA  mismatch
repair  genes  –  PMS2,  MLH1 and MSH2 –  are  associated with  type-1  Turcot  syndrome.
Interestingly, type-1 Turcot syndrome also is associated with café au lait spots [84]. Con‐
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versely,  type-2 Turcot syndrome families have medulloblastomas as their  most common
CNS malignancy, and multiple adenomatous polyps that often undergo malignant trans‐
formation [99].  Unfortunately, medulloblastomas, glioblastomas and anaplastic astrocyto‐
mas  are  the  most  common  CNS  tumors  observed  in  Turcot’s  syndrome,  the  three
combined  accounting  for  95% of  all  CNS tumors  in  these  families  [100];  and  the  latter
two  are  inevitably  fatal.  In  addition,  they  tend  to  occur  early,  with  medulloblastomas
typically diagnosed in children less than 10 years old, and gliomas in those under age 30
[84],  [101]-  [103].  As  such,  and because  some die  of  metastatic  colon cancer  that  some‐
times presents quite early in childhood or the second decade of life, many die as adoles‐
cents or young adults. In one tragic case, for example, doctors in Pittsburgh reported the
case of  a  girl  who developed a medulloblastoma at  the age of  5  years.  Ten years  later,
she  developed  adenocarcinoma  of  the  colon.  Then,  seven  months  after  resection  of  a
Dukes' C2 adenocarcinoma, she presented with a second primary CNS tumor, this time a
glioblastoma multiforme [101].
Rubenstein-Taybi syndrome is an autosomal dominant disorder that is associated with
numerous anatomical/functional abnormalities that include abnormal facies, microcephaly,
broad thumbs, big toes and moderate to severe intellectual impairment. There also is an
increased incidence of neuroepithelial tumors - in particular medulloblastomas, meningiomas,
and oligodendrogliomas [104], though other CNS tumors have been described [105]. A germ-
line mutation in one allele of CRE binding protein (CBP, a transcriptional co-activator for
several c-AMP regulated genes) has been implicated in many cases. CBP binds to the activated
form of GLI, a transcription factor that is important in the regulation of the Sonic the hedgehog
homolog (SHH) that, as stated earlier, controls cell division in adult stem cells and has been
implicated in oncogenesis. The GLI gene is downstream of the PTCH1 gene that is mutated in
basal cell nevus syndrome.
6. Ollier’s disease and Maffucci syndrome
Enchondromatosis, also called dyschondroplasia, is a hamartomatous proliferation of chon‐
drocytes within the metaphysis of bone [106]. Though often asymptomatic and only diagnosed
as an incidental X-ray finding, it can lead to significant deformities, reduced bone length [107],
[108], and occasional pathologic fractures [108]. Moreover, just like the phakomatoses and
familial syndromes like Li-Fraumeni and Turcot syndrome, enchondromatosis appears to
confer a substantial increased risk of a variety of CNS and other malignancies, at least through
the sixth decade of life and as early as the first decade. These tumors include chondrosarcomas
that result from sarcomatous transformation of the enchondromas themselves, as well as other
histologically-distinct malignancies like angiosarcomas, osteosacrcomas, ovarian tumors,
various leukaemias, and a variety of glial-cell based central nervous system tumors (ranging
from stage I to stage IV astrocytomas) [109]. This association with malignancy appears to be
particularly true in instances of multiple enchondromatoses, as in Ollier’s disease and
Maffucci’s syndrome [110], two very rare conditions [111], [112].
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Since Boinet first reported CNS malignancy in a patient with multiple enchondromatosis, [113]
45 additional patients with either Ollier’s disease (OD) or Maffucci’s syndrome (MS) and some
form of intracranial malignancy have been reported in the medical literature, ranging from 6
to 58 years old [114]. Ollier’s disease patients appear to contract their neoplasms at a particu‐
larly early age, including very young childhood [109], [114], [115]. What causes this persistent
increase in malignancy potential is not yet known. We do know that single enchondromas,
outside some greater syndrome, are associated with an elevated risk of malignant change.
Altay et al [116], for example, conducted an 18-year retrospective analysis of 627 cartilage-
forming benign bone tumors, and found that 32 patients had experienced malignant transfor‐
mation, with 14 of these 32 patients initially having had a solitary osteochondroma, ten
multiple osteochondromas, six a solitary enchondroma, one Ollier's disease, and one Maffuc‐
ci's syndrome. The one patient with Ollier's disease had two chondrosarcomas; and the single
patient with multiple osteochondroma had three chondrosarcomas. The overall rate of
malignant transformation for cartilage-originating tumors was 5.1%, being 4.2% for solitary
osteochondromas, 9.2% for multiple osteochondromas, and 4.2% for solitary enchondromas.
A variety of chromosomal abnormalities also have been reported in isolated cases of OD or
MS and chondrosarcoma. These abnormalities include, for example, the interstitial deletion,
del(1)(p11p31.2), as the only chromosomal abnormality identified in a low-grade chondrosar‐
coma in a patient with Ollier’s disease [117]. Also, Bovée et al [118] identified (1) the loss of
heterozygosity (LOH) in a tibial chondrosarcoma and its metastases, exclusively on chromo‐
some bands 13q14 and 9p21, with the LOH not identified in a femoral enchondroma that was
analyzed; and (2) p53 over-expression in a tibial chondrosarcoma and its metastases, not
present in a femoral enchondroma. Meanwhile, Chang et al [119] identified identical male twins
with OD who both developed astrocytomas within their cerebral cortex during their early
twenties; and Robinson et al [120] found evidence of mitogenic neurotransmitters within both
enchondromas and soft tissue hemangiomas in a patient with Maffucci’s syndrome, implying
that the bone and vascular lesions, and possibly malignant tumors, might be related to an
underlying neural abnormality. Having said all this, to date, no consistent chromosomal
abnormalities have been identified in these patients, and all theories regarding the cause of
malignancies in these syndromes remain unproven.
6.1. Ionizing radiation
The first report of a radiation-induced CNS tumor was by Mann et al in 1953 [121]. He described
the case of a 3 year-old girl, born in 1942, who presented with a left optic nerve astrocytoma
that was excised and then irradiated with a total dose over time of 6,500 rads. Six years later,
at age 9, she presented with her first episode of recurring frontal meningiomas, which
subsequently underwent malignant change, leading to her death at age 10. At about the same
time, two independent groups were reporting on the 1.5 to 2-fold increased risk of cancers,
including brain cancers, in children exposed to X-rays in utero [53], [122]- [124]. Subsequently,
more than 280 radiation-induced intracranial tumors have been reported in the literature, the
most common being meningiomas, sarcomas, and gliomas, though ependymomas, Schwan‐
nomas, PNETs, and pituitary adenomas have been described as well [125]. Consequently, the
association between therapeutic radiation to the head and the subsequent risk of brain cancer
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has been well-established, especially since a landmark study performed in Israel and published
in 1988 [126]. In this study, the relationship between radiotherapy in childhood for tinea capitis
and the later development of tumors of the brain and nervous system was evaluated in 10,834
patients treated between 1948 and 1960. Benign and malignant tumors were identified from
the pathology records of all Israeli hospitals and from Israeli national cancer and death
registries. Doses of radiation were estimated retrospectively for each patient (mean, 1.5 Gy).
The incidence of tumors was 1.8 per 10,000 persons per year, and the estimated relative risk
(RR) versus 10,834 matched general-population controls and 5392 non-irradiated siblings 6.9
(95% confidence interval 4.1-11.6) for all tumors and 8.4 (4.8-14.8) for neural tumors of the head
and neck. Increased risks were observed for meningiomas (RR = 9.5), gliomas (2.6), nerve-
sheath tumors (18.8), and other neural tumors (3.4). Moreover, a strong dose-response
relationship was identified, with relative risk approaching 20 beyond estimated doses of 2.5
Gy. Radiotherapy also was associated with an increased risk of death from tumors of the head
and neck, including brain cancers (RR = 3) and leukemia (RR = 2.3) [127].
In an earlier case-control study, 2,215 patients in New York who during childhood had been
given x-ray therapy for tinea capitis between 1940 and 1959 were compared against 1,395
persons matched for age, sex, and race and also treated for tinea capitis over the same period
without x-ray therapy [128]. Excess incidence was noted in irradiated cases of tumors of the
head and neck, including the skin, brain, thyroid, and parotid. However, there was no
increased mortality from malignant neoplasms or any other cause. In another study, diagnostic
X-rays of the head and neck increased the odds of brain tumors by 64% (OR 1.64; 95%CI,
1.04-2.58). [129] Thierry-Chef et al has estimated that the life-time increase in brain cancer risk
among pediatric patients receiving radiation to the brain ranges from 2 to 80%, depending
upon the dose and conditions of exposure [130]. There is, however, a huge range in the latency
time between irradiation and subsequent brain tumor development, from 4 to 47 years among
27 cases described by Chowdhary et al. [125] Clearly, some such tumors may arise in childhood,
and others much later.
7. Suspected/possible risk factors
In addition to risk factors that have been established through consistent results across several
studies, there are several suspected or possible risk factors for which data are either scarce or
conflicting. Difficulties that arise from the study of these risk factors include their somewhat
ubiquitous exposure (e.g., electromagnetic fields), difficulties measuring exposure (e.g., diet,
parental occupation), and their relative novelty (e.g., cell phones and other hand-held electric
devices).
7.1. Electromagnetic fields
Over the past few decades, considerable research has been compiled supporting the association
between electromagnetic field (EMF) exposure and childhood leukemia, such that the Inter‐
national Agency for Research on Cancer has classified extremely-low-frequency magnetic field
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exposure as a possible human carcinogen [131]. However, data linking EMF exposure and
brain cancer are much less conclusive [131]- [135]. Most older studies suffered from various
methodological issues, like the problem of inadequate blinding of those evaluating EMF
exposure, and crude measurements of actual exposure [53]. The first studies to overcome these
short-falls were conducted in Denver, Colorado by Savitz et al. who, in their initial study, had
blinded assessors evaluate the power-line configurations of the homes of all 356 residents in
the five-county 1970 Denver, Colorado Standard Metropolitan Statistical Area between 0 and
14 years of age who had been diagnosed with any form of cancer between 1976 and 1983;
among them were 59 confirmed cases of brain cancer [136]. The odds ratio comparing very
high and high wire codes versus very low, low, and buried wire codes was 1.5 (95% CI = 1.0-2.3)
for total cases, with OR = 2.0 for brain cancer. Subsequently, this same group studied the effect
on childhood cancer of prolonged exposure to 60-H magnetic fields from electric appliances
comparing Denver area children 0-14 years old whose incident cancers had been diagnosed
between 1976 and 1983 versus controls selected by random digit dialing, matched for age, sex,
and telephone exchange area. Parents of 252 cases and 222 controls were interviewed at home
about the use of electric appliances by the mother during pregnancy (prenatal exposure) and
by the child (postnatal exposure). After adjusting for income, prenatal electric blanket exposure
was associated with a significant increase in the incidence of childhood brain cancer (OR = 2.5,
95% CI 1.1-5.5) [137]. Subsequently, Savitz et al assessed for risk in the same Denver population
by comparing risks by high wire code (HWC) versus low wire code (LWC) classifications using
the Wertheimer-Leeper coding method, modified by eliminating the distinction between thick
and thin primaries, distinguishing only between open and spun secondaries, and reducing the
number of categories from five to three [138]. The association between the modified code and
measured magnetic fields was similar to the association with the original wire code. Residences
assigned the high wire code had odds ratios of 1.9 for total cancers (95% CI: 1.1-3.2), 2.9 for
leukemias (1.5-5.5), and 2.5 for brain cancer (1.1-5.5), after adjusting for all other measured
potential risk factors for childhood cancer.
In 2001 [134] and again in 2010 [139], Kheifets et al reviewed all major studies published on
the association between EMF and childhood brain cancers published to date and found that,
where the earlier studies by investigators like Wertheimer and Leeper [140], Savitz et al [136]-
[138] and Tomenius [141] identified an association between EMF exposure and increased brain
cancer risk, later studies and reviews by investigators like Preston-Martin et al [142], Gurney
et al [132], Feychting et al [143], Kheifits et al [133] generally failed to confirm this risk. In their
2010 meta-analysis of brain cancer risk with extremely low-frequency EMF, Kheifits et al
subdivided studies in terms of both the methodology of EMF measurement (long-term,
calculated fields, or spot measurement) and the type of home exposure (home at the time of
cancer diagnosis, longest-lived-in home, and birth home) and found no significantly elevated
odds ratios for any of the six categories, even with exposures ≥ 4µT [139]. This conclusion, that
there are no conclusive data linking EMF exposure with brain cancer risk has been echoed by
others [144], [145].
Relatively few papers have looked at the use of computers, per se. Both Mutnik et al and Wood
specifically assessed the risk of computer use in terms of brain cancer development, and neither
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identified any significant risk [146], [147]. However, both papers were written in the 1990s,
before the recent surge in home computer use, and long before prolonged exposures (e.g., 10
years or greater) to home computers could have occurred.
In one clever paper in which the pros and cons of the association between EMFs and childhood
brain cancer were debated by two teams, each composed of eight international experts, using
12 pre-determined questions, arguments on both sides ultimately concluded that further
research is necessary, an opinion vigorously championed by Carpenter in his paper Electro‐
magnetic fields and cancer: the cost of doing nothing [10]. However, contributing to the confusion
regarding EMF exposure are a number of methodological issues pertaining to the measure‐
ment of EMF, both in and around residences and in the workplace, issues that have sparked
almost as much debate and research as the question of EMF exposure’s role in disease [143],
[148]- [154]. Such issues include questions about the accuracy of EMF measurements, how to
avoid bias in subject selection, where best to measure EMF exposure (e.g., a child’s bedroom
versus elsewhere in or around the home), how to deal international variations in wiring
techniques, how to interpret changes in electrical wiring over time and their effects, and how
to adjust for the myriad of other potential confounders like other household exposures and
exposures, EMF and otherwise, outside of the home. This last issue is, in fact, a problem with
virtually all of the suspected or potential risk factors that are discussed here, including cell
phones and other hand=held electronic devices, which are the topic of the next section.
7.2. Cell phones and other hand-held devices
Over the past 15 years, there has been a virtual explosion in the use of hand-held cellular
devices like cell phones, iPods, iPads, Kindles, and other electronic reading devices. For
example, whereas uncommon in use in 1995, as of 2011, there were more than 4.6 billion active
mobile telephone subscriptions worldwide [155]. This has led to considerable concern
regarding the impact such devices might have upon health and, in particular because of the
issues raised with EMFs, upon brain cancer and leukemia rates.
Over the last decade, most data on cell-phone use and cancer risk have come from the 13-
country INTERPHONE Study, and from Sweden, and the results from these two sources have
been somewhat conflicting. In Sweden, most of the data has been collected by the research
group of Hardell et al. [129], [156] In their most recent study, analysis was performed pooling
data from two case-control studies on patients with malignant brain tumors diagnosed from
1997 through 2003 compared against matched controls alive at the time of study inclusion, and
a third case-control study on deceased patients and controls diagnosed over the same time
period [157]. In total, 1,251 (85%) cases and 2,438 (84%) controls were identified. Brain cancer
risk was noted to increase with latency period and cumulative use in hours, both for mobile
and cordless phones. The greatest level of risk was identified for astrocytoma, the odds ratio
(OR) for the longest (>10 year) latency group for mobile phone use equal to 2.7 (95% CI, 1.9-3.7)
and for cordless phone use 1.8 (1.2-2.9). The risk of astrocytoma was highest in the group with
first use of a wireless phone before the age of 20 (mobile phone use OR = 4.9, 95% CI = 2.2-11;
cordless phone use OR = 3.9, 95% CI = 1.7-8.7). Earlier, Hardell et al had reported on their
comparison of mobile phone use in deceased brain cancer cases relative to controls who had
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died from another type of cancer other than brain tumor, and to controls who had died from
other diseases. Exposure was assessed by a questionnaire sent to the next-of-kin. Replies were
obtained for 346 (75% participation rate) cases, 343 (74%) cancer controls and 276 (60%) controls
with other diseases. Use of mobile phones was associated with an increased risk of brain cancer
that was highest in the >10-year latency group, with an odds ratio of 2.4, (1.4-4.1). The risk
increased with cumulative number of lifetime hours for use, and was highest in those with
more than 2,000 hours of mobile phone use (OR = 3.4; 1.6-7.1). No clear association was found
for the use of cordless phones, though OR was 1.7 (0.8-3.4) among those with >2,000 h of
cumulative use [158]. These findings were interpreted as supporting earlier findings by this
group in other studies.
The INTERPHONE Study has been a multinational case-control study designed to investigate
whether mobile phone use increases the risk of cancer and, more specifically, whether the RF
fields emitted by mobile phones are carcinogenic [159]. As such, the study has focused on
tumors that arise within those tissues most exposed to the RF fields emitted by mobile phones
on the same (ipsilateral) side as phone use. In addition to collecting detailed histories on mobile
phone use, information has been collected on a number of known and potential risk factors
for these tumors. The study has been conducted in 13 countries: Australia, Canada, Denmark,
Finland, France, Germany, Israel, Italy, Japan, New Zealand, Norway, Sweden, and the UK
using a common core protocol. Enrolled in the study have been 2,765 individuals with gliomas,
2,425 with meningiomas, 1,121 with acoustic neuromas, 109 with malignant parotid gland
tumors and 7,658 controls. In addition to assessing brain cancer risk, particular attention has
been paid to estimating the amount and direction of potential recall and participation biases
and their impact upon study results. Results have been presented for countries individually
with consistently no statistically-significant within-country association identified between
phone use and brain cancer identified, as in Germany [160], [161], France [162], Sweden [163],
and Japan [164]. One exception was in Israel, where the odds ratios (OR) for benign and
malignant parotid gland tumors in the highest category of cumulative number of calls and call
time without use of hand-free devices were 1.58 (95% confidence interval: 1.11, 2.24) and 1.49
(1.05, 2.13), respectively [165].
When INTERPHONE data from multiple countries has been compiled, there has been a
significantly increased risk of glioma (OR = 1.40; 95% CI 1.03-1.89), but only among those in
the highest 10% of recalled cumulative call time (more than 1640 h). Any increased risk was
not statistically significant for meningiomas (OR = 1.15; 0.81-1.62) [166]. One issue raised by
the investigators was that there were implausible values of reported use in the highest user
group. Odds ratios for glioma did tend to be greater in the temporal lobe than in other lobes
of the brain, but the CIs around the lobe-specific estimates were wide. The ORs for glioma also
tended to be greater in subjects who reported usual phone use on the same side of the head as
their tumor than on the opposite side. In terms of actual exposure, represented by total
cumulative specific energy (TCSE; J/kg), when 553 glioma and 676 meningioma cases of brain
tumor from the Australian, Canadian, French, Israeli and New Zealand components of the
Interphone Study, whose tumors were localised by neuroradiologists, were compared with
controls matched for age, sex and region, and compared against 1762 and 1911 controls,
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respectively, ORs for glioma were below 1.0 within the first four quintiles of TCSE, but above
1.0 in the highest quintile, 1.35, approaching but not quite achieving statistical significance
(95% CI 0.96 to 1.90) [167]. In a complementary analysis in which 44 glioma and 135 meningi‐
oma cases in the most exposed area of the brain were compared against gliomas and menin‐
giomas located elsewhere, increased ORs were noted for tumors in the most exposed part of
the brain in those with 10 or more years of mobile phone use (OR 2.80, 95% CI 1.13 to 6.94 for
glioma). And, in pooled analysis across the four Nordic countries and the UK, increased risk
of a tumor on the same side of the head as reported phone use that has persisted for ≥ 10 years
was noted (OR = 1.8, 95% CI: 1.1-3.1) [168].
No increased risk of acoustic neuroma was identified in any study [169]. Overall, the INTER‐
PHONE investigators concluded that there were no conclusive data linking cell-phone use and
risk of brain malignancies, except after prolonged and exorbitant use. Criticisms have been
made of the INTERPHONE studies, however, relating, among other issues, to recall and
misclassification biases potentially exacerbated by low response rates [170]- [172].
In a meta-analysis drawing from both sets of studies (Hardell et al and INTERPHONE),
Hardell et al found that the odds ratio for glioma (1.0; 95% CI, 0.9-1.1) increased to 1.3 (1.1-1.6)
after a 10-year latency period, with the highest risk identified for ipsilateral exposure (OR=1.9;
1.4-2.4) versus OR=1.2 (0.9-1.7) with contralateral exposure [173]. The odds of acoustic neuroma
(OR=1.0; 0.8-1.1) also increased after a 10-year latency period, but just failed to achieve
statistical significance (OR=1.3; 0.97-1.9), except when ipsilateral exposure was considered
alone (OR=1.6; 1.1-2.4). No consistent pattern of increased risk was uncovered for meningio‐
mas. In terms of age, the highest risk of brain cancer was identified among those who were
under 20 years of age at the time they first started using wireless phones.
Outside these two sources of multiple studies, another source of data stems from the previ‐
ously-mentioned SEER database in the U.S., drawing from which Little et al compared
epidemiological data from 12 registries (Atlanta, Detroit, Los Angeles, San Francisco, San Jose-
Monterey, Seattle, rural Georgia, Connecticut, Hawaii, Iowa, New Mexico, and Utah) against
incidence trends reported by the INTERPHONE Study Group and Hardell’s group in Sweden
[174]. U.S. population-based data was evaluated for glioma incidence from 1992 to 2008, a
period of time during which mobile phone use increased dramatically from virtually 0% to
almost 100% of the U.S. population. During these years, 24,813 non-Hispanic Caucasians 18
years or older were diagnosed with glioma. Age-specific incidence rates of glioma remained
generally stable from 1992 to 2008 (-0.02% change per year, 95% confidence interval -0.28% to
0.25%), despite the exponential increase in cell-phone use. The authors concluded that the
decline in brain cancer rates they observed was inconsistent with the association between brain
cancer and mobile phone use conjectured by Hardell’s group, since rates should have been at
least 40% higher than observed. On the other hand, they felt that the SEER data could be
consistent with the glioma rates predicted based upon the small proportion of highly-exposed
individuals reported in the INTERPHONE study.
Overall, results on the association between mobile phone use and brain cancer certainly might
be considered suggestive, particularly in terms of long-term risk after years of exposure to cell
phones, especially when used extensively. However, in two just-published reviews, Swerdlow
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et al [155] and Repacholi et al [11] both noted the inconclusiveness of current data, and on the
limitations imposed by the absence of data both on exposures beyond 10 to 15 years, and on
childhood cancers. Echoing Carpenter’s concerns about EMF exposures in general [10], what
is potentially alarming is the potential for further increases in brain cancer risk after latencies
beyond ten years, especially given the now almost-universal use of cell phones and other hand-
held electronic devices by adolescents and children.
7.3. Diet (maternal diet during pregnancy/childhood diet)
Many of the same methodological issues and sources of potential bias (e.g., recall and ascer‐
tainment bias) pertain to maternal and childhood diet as to electromagnetic field exposure,
rendering research to address the association between diet and childhood brain cancer
difficult. For that reason, the research into this issue is, again, inconclusive. The most consis‐
tently positive association between diet and childhood brain cancer risk has been for cured
meats, like hot dogs. In Denver, Colorado, cured and broiled meat consumption by mothers
during pregnancy and by children themselves was assessed in 234 childhood cancer cases
(including 45 brain tumor patients) and 206 controls selected by random digit dialing [175].
Five meat groups (ham, bacon, or sausage; hot dogs; hamburgers; bologna, pastrami, corned
beef, salami, or lunch meat; charcoal-broiled foods) were assessed. Exposures among U.S.
standard metropolitan statistical areas were compared, with adjustments made for confound‐
ers. Maternal hot dog consumption once or more weekly was statistically associated with
childhood brain tumors (OR = 2.3, 95%CI, 1.0-5.4). Meanwhile, among children, eating
hamburgers once or more times per week was associated with a non-statistically increased risk
of ALL (OR = 2.0, CI = 0.9-4.6), as was eating hot dogs once or more times weekly with brain
tumors (2.1; 0.7-6.1). However, among children, the combination of no vitamins and eating
cured meats was associated more strongly with both ALL and brain cancer than either no
vitamins or meat consumption alone, producing ORs between 2 and 7, suggesting possible
adverse effects of dietary nitrites and nitrosamines.
Bunin et al and the Children’s Cancer Group conducted a case-control study specifically
assessing the effects of maternal diet during pregnancy on the risk of childhood astrocytoma
in 155 cases and 155 matched controls, all under age six, the controls selected by random-digit
dialing [176]. A trend again was observed for consumption of cured meats (adjusted odds ratio
[OR] for the highest versus lowest intake quartile = 1.7, p = 0.10). Iron supplements were
associated with a significant decrease in astrocytoma risk (OR = 0.5, 95%CI, 0.3-0.8). No
significant trends were observed for nitrosamine (OR = 0.8, p = 0.60); nitrites (1.3, p = 0.54);
nitrates (0.7, p = 0.43); vitamin C (0.7, p = 0.37); or vitamin E (0.7, p = 0.48). Unfortunately,
income level was a potential confounder.
In yet another high-profile case-control study, Bunin et al examined maternal diet relative to
the risk of primitive neuroectodermal tumors (PNET) of the brain in offspring, with all 166
cases again under the age of six years at diagnosis [177]. As in the previously-mentioned study,
controls were selected by random-digit dialing and matched for age and race. Telephone
interviews with mothers included questions on the frequency of consumption of alcohol,
vitamin and mineral supplements, and 53 specific foods during pregnancy. Significant
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protective trends were observed for vegetables (OR for the highest versus lowest quartile
group for intake, 0.37; p = 0.005), fruits and fruit juices (OR = 0.28; p = 0.003), vitamin A (0.59;
p = 0.03), vitamin C (0.42; p = 0.009), nitrate (0.44; p = 0.002), and folate (0.38; p = 0.005). Taking
iron (0.43; p = 0.004), calcium (0.42; p = 0.05), and vitamin C (0.35; p = 0.04) supplements at any
time during pregnancy and multivitamins over the first six weeks (0.56; p = 0.02) all were
associated with decreased risk. On multivariate analyses, folate, early multivitamin use, and
iron supplements remained protective [177]. A non-significant trend of increasing risk was
observed for nitrosamine consumption (1.65; p = 0.15).
Concerns over the consumption of nitrates, nitrites and nitroamines have been expressed by
others, given the susceptibility of rats to develop brain tumors in response to N-nitroso urea
exposure, the morphological similarity between these tumors and those observed in humans,
and the presence of nitrate salts in many fertilizers [178]. Consistent with this potential risk,
one meta-analysis of brain cancer risk in U.S. farmers yielded a relative risk of 1.30 (95% CI,
1.09, 1.56) [179], though pesticides, to which farmers also often are exposed, are another
potential explanatory factor. In yet another case-control study, an increased risk of childhood
astrocytomas was detected in association with in utero exposure to nitrites via a residential
water source [180].
7.4. Environmental neurocarcinogens and parental occupation
As confusing and diverse the literature on EMF and diet is, it is even more so with respect to
environmental and occupational exposures, due to the difficulties ascertaining and quantify‐
ing levels of exposure, especially when that exposure is second-hand to a child.
Pesticide exposure, both first-hand and second-hand, has been shown to be associated with
increased brain cancer risk in children in a number of studies; but effects have tended to be
modest and sometimes conflicting. Daniels et al [181] reviewed the results of 31 studies
published between 1970 and 1996 and noted methodological issues in most of them, including
small sample sizes, inadequate measurement of actual exposure, and potential biases related
to the selection of controls. A further inconsistency was the lack of an effect of direct exposure
to the child in studies in which an effect of parental occupational exposure was identified, a
clearly counter-intuitive discovery [181]. Risks also varied with the type of pesticide and type
and level of exposure. For example, Shim et al compared 526 brain cancer cases diagnosed
before age 10 years and identified from statewide cancer registries of four U.S. Atlantic Coast
states versus one-to-one-matched controls selected via random digit dialing [182]. Exposure
risk was assessed through computer-assisted telephone interviews with mothers. Using
information on residential pesticide use and jobs held by fathers over the 2-year period prior
to the child's birth, potential exposures to insecticides, herbicides, and fungicides were
estimated. For each occupation, two raters independently classified the probability and
intensity of exposure. A significantly increased risk of astrocytoma was associated with
exposures to herbicides from residential use (OR = 1.9; 95% CI, 1.2-3.0). Combining parental
exposures to herbicides from both residential and occupational sources, the elevated risk
remained significant (1.8; 1.1-3.1). Little association was observed with primitive neuroecto‐
dermal tumors (PNET) for any of the pesticide classes or exposure sources considered. In
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another study, the risk of childhood brain cancer was again assessed relative to parental
exposure to different classes of pesticide in 154 children diagnosed with astrocytoma and 158
children diagnosed with primitive neuroectodermal tumors (PNET) in the United States and
Canada between 1986 and 1989 [183]. Controls again were selected by random digit dialing
and were individually matched to cases by race, age, and geographic area. Each job in the
fathers' work history and the usual occupation of mothers were assigned a probability,
intensity, and frequency of exposure to insecticides, herbicides, and agricultural and non-
agricultural fungicides. Elevated risks of astrocytoma were identified for paternal exposure
(ever vs. never) to all four classes of pesticides (odds ratios (OR) = 1.4-1.6), while an increased
risk of PNET was observed only for herbicides (OR = 1.5). For mothers, odds ratios for
astrocytoma were elevated for insecticides, herbicides, and non-agricultural fungicides (OR =
1.3-1.6) but not agricultural fungicides (OR = 1.0). Concerns have been raised about the
accuracy of the levels of probability, intensity, and frequency of exposure assigned to mothers
and fathers. Interestingly, both studies that assessed the use of no-pest strips within the home
identified increased childhood brain cancer risk [184], [185]. In the study by Leiss et al, this
effect was dose dependent, with the odds ratio of brain tumors equal to 1.5 (95%CI, 0.9-2.4)
when exposure was limited to just the last three months of pregnancy, versus 1.8 (1.2-2.9) when
exposure was for the full two years prior to and throughout pregnancy [185]. One potential
mechanism for direct pesticide-induced cancer risk is their conversion via nitrites in the
stomach into potentially-carcinogenic N-nitroso compounds [186]; though how this might
affect an unborn child is unclear.
Hair dyes are another environmental and occupational neurocarcinogen that has been shown
to significantly increase brain cancer risk. In a population-based case-control study involving
112 white women in Nebraska newly diagnosed with glioma between July 1988 and June 1993,
versus 215 controls, a 1.7-fold increased risk of glioma was observed among those who had
ever used hair coloring products (95%CI = 1.0-2.9) [187]. This risk increased to 2.4 among those
who had used permanent hair coloring products (95%CI, 1.3-4.5), and the risk of glioblastoma
increased with duration of exposure, to 4.9 (95% CI, 1.6-15.7) after 21 or more years of perma‐
nent hair color use. Higher risks also were observed with earlier age at first use. In another
study, the risk of brain cancer among children born on or after 1980 to women who had
personally used hair dyes over the five years prior to pregnancy was increased 11-fold, though
the confidence limits were broad (95%CI, 1.2-90) [188]. Childhood brain cancers also were
associated with non-work-related maternal exposure to any beauty products (OR = 2.6, 95%CI,
1.2-5.9) and to hair sprays (3.4; 1.0-11).
Choi et al identified a significant risk of childhood brain cancer before age 5 in women living
within one mile of a facility releasing toxic release inventory (TRI) chemicals while pregnant
[189]. In 2008, Clapp, Jacobs and Loechler published a detailed review of environmental and
occupational causes of cancer, a 40-page manuscript with extensive tables that list all chemicals
and other environmental exposures associated with a variety of cancers. For brain cancers,
evidence of an association is considered strong only for ionizing radiation [180].
Occupational exposures have been assessed both for the mother and father, but especial‐
ly  the  latter,  in  terms  of  child  cancer  risk  [4].  Besides  farming/agriculture,  associations
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have  been  reported  for  the  aircraft,  electronics,  petroleum,  and  pulp  and  paper  indus‐
tries, as well as for any industries associated with increased exposures to paints, solvents,
other chemicals, pesticides, ionizing radiation, and electromagnetic fields [4], [190]. Albeit
now more than 20 years old, Savitz and Chen wrote a very thorough paper summarizing
all studies performed to date assessing the risk of childhood brain cancers, hematopoietic
malignancies, and other malignancies relative to both paternal and maternal occupations
[191].  Occupations  were  subdivided  into  motor  vehicle  related  occupations,  machinist
and factory workers,  occupations with paint  exposure,  occupations with chemical  expo‐
sure,  the  petroleum  industry,  occupations  with  exposure  to  aggregated  hydrocarbons,
electronics,  occupations associated with ionizing radiation, occupations with metal expo‐
sure,  agriculture,  construction,  pulp  and  paper,  aerospace  and  aircraft  industries,  and
other occupations (printing workers,  graphic arts  workers,  and glass,  clay and stone in‐
dustry).  For virtually every occupational category, there was at least one study identify‐
ing  a  statistically  increased  odds  ratio  for  childhood  nervous  system  cancer.  Table  2
summarizes that  list,  noting the number of  studies  in each job category,  the number of
studies with an odds ratio for childhood brain cancer > 1.0,  the number of studies with
an odds ratio  statistically  greater  than 1.0,  and the range of  odds ratios  within that  job
category.
Note that, in no category for which there was more than a single study, was every odds ratio
for childhood brain cancer statistically greater than one. Note also that the industries in which
all odds ratios were > 1.0, even if not statistically significant, were the petroleum industry,
electrical work, metal work, and pulp and paper. Note also that some industries, like health
care, were not mentioned. Among mothers, the odds ratios for childhood brain cancer were
3.3 for occupations with chemicals on the skin, 3.0 for occupations involving inhaled chemicals
of fumes, 1.6 for bakers, and 4.0 for occupations requiring protective clothing or equipment
[191]; only the last OR was statistically greater than 1.0.
In a later and also quite thorough review of the literature, published in 1998, Colt and Blair
reviewed 48 papers published between 1974 and 1987, encompassing relative risk estimates
for over 1000 specific cancer/occupation and cancer/exposure combinations [192]. Of these
papers, 23 contained data assessing the relationship between paternal occupations and
childhood nervous system cancers other than neuroblastoma; maternal occupations only were
evaluated in terms of childhood leukemia risk. In table form, these authors listed studies by
exposure, categorizing into electromagnetic fields; paints and pigments; hydrocarbons; metals;
and motor vehicle-related occupations. These results are summarized in Table 3.
As in the review by Savitz and Chen, the results were conflicting, the authors themselves
concluding that the evidence was strongest in support of an association between paternal
exposure to paints and pigments [192]. Results on maternal occupations were scant and yielded
no statistically significant associations.
More recently published studies yield much the same diffuse and inconsistent results [193]-
[196], including one recently published study (2008) in Taiwan in which no associations among
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202 young brain cancer cases, ages 0 to 29 years, were identified across a wide variety of
occupations [197].
Finally, in one novel study, Rosso et al examined whether or not there was an association
between a father’s hobbies and brain cancer risk in their child, specifically looking at medul‐
loblastomas and other PNET in 318 children under age 6 versus 318 randomly selected
population controls [198]. On multivariate analyses, the only significant association was for
lawn care with pesticides [during pregnancy: odds ratio (OR) = 1.6, 95% confidence interval
(CI): 1.0, 2.5; after birth: OR = 1.8, 95% CI: 1.2, 2.8].
7.5. Other potential risk factors
Numerous other risk factors for childhood brain cancer have been reported, albeit mostly in
single studies. Neonatal head circumference was found to be associated with an increased risk
Occupation/Main Exposure Number of studies Number of OR "/>
1.0
# OR statistically "/>
1.0
Range of OR
Motor vehicles 7 3 1 0.6 - 2.8
Machinist & factory workers 5 3 1 0.7 - 4.4
Paint 4 3 1 1.0 - 7.0
Chemicals 6 5 3 0.8 - 10.0
Petroleum 3 3 0 1.3 - 3.1
Aggregated hydrocarbons 6 4 1 0.5 - 3.2
Electrical 4 4 2 1.6 - 11.8
Ionizing radiation 6 5 2 1.0 - 2.2
Metals 3 3 1 1.6 - 2.7
Agriculture 4 2 n/a 0.6 - 2.0
Construction 4 3 2 0.9 - 2.3
Pulp & paper 3 3 1 1.6 - 4.0
Aerospace & aircraft 3 2 1 1.0 - ∞*
Printing workers 1 1 1 4.5
Graphic arts 1 1 1 21.9
Glass, clay, stone 1 1 0 1.5
Total 61 46 18 0.5 - ∞*
Savitz and Chen, 1990 [1] [9] [1]
* ∞ = infinity
Table 2. Paternal Occupation and Childhood Nervous System Cancer Risk
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of brain cancer by Samuelson et al, who analysed 1,010,366 individuals with 12,378,172 person-
years of follow-up, from which 453 individuals ages 0 to 15 years were diagnosed with brain
cancer [199]. In this population, the relative risk of brain cancer was 1.27 (95%CI 1.16-1.38) for
every 1 cm increase in head circumference, after adjusting for birth-weight, gestational age,
and gender. In another study of 746 invasive CNS cancers in children less than 4 years old,
after adjusting for parental education, elevated birth-weight was associated with an odds ratio
of 1.71 for astrocytoma (95%CI, 1.01-2.90); but birth weight was not associated with an
increased risk of PNET [42].
Prior malignancy has been associated with a variety of malignancies in the literature, including
brain cancer. Some of this increased risk almost certainly is secondary to radiation therapy to
the head and neck [129]. Yet even when head irradiation is not utilized, brain cancer risk may
be increased. Maule et al identified a total of 133 second malignant neoplasms in 16,540 patients
with hematopoietic malignancies (12,731 leukemias, 1246 Hodgkin’s lymphomas, and 2563
non-Hodgkin’s lymphomas) after an average follow-up of 6.5 years [200]. The most frequent
second malignancies after leukemia were brain cancer (standardized incidence ratio [SIR] =
8.52; 95% CI = 5.13 to 13.3), non-Hodgkin’s lymphoma (SIR = 9.41; 4.30 to 17.9), and thyroid
cancer (SIR = 18.8; 8.60 to 35.7). The most frequent after non-Hodgkin’s lymphoma were
thyroid cancer (SIR = 40.4; 14.8 to 88.0) and brain cancer (SIR = 6.97; 1.90 to 17.9). There was no
increased incidence of brain cancer following Hodgkin’s lymphoma.
In Rio de Janeiro, in a hospital-based case-control study involving 231 adults with primary
brain tumors and 261 controls matched for gender and age among in-patients hospitalized for
various conditions unrelated to brain cancer, past head injury was found to be significantly
more frequent among cases (46%) than controls (36%) (OR(adjusted) = 1.49; 95%CI = 1.03-2.15)
[201]. Moreover, a dose-response effect was observed related to the number of head injuries,
and a statistically-borderline association was observed specifically for meningioma (OR(adj)
= 1.63; 0.96-2.75). These results have not yet been replicated and, to date, no such association
has been identified for childhood brain cancer.
Main Exposures # RR estimates Number of RR "/> 1.0 # RR statistically "/> 1.0 Range of RR
Electromagnetic fields 55 45 9 0.3 - 73.3
Paints & pigments 14 13 4 1.0 - ∞
Hydrocarbons 28 12 2 0.4 - 4.0
Metals 17 15 4 0.8 - 5.3
Motor vehicles, etc. 32 12 2 0.1 -5.9
Total 146 97 21 0.1 - ∞
Colt and Blair, 1998 [192]
* ∞ = infinity
Table 3. Paternal Occupation and Childhood Nervous System Cancer Risk
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In a nationwide Danish study on the occurrence of cancer among 8,093 Danish individuals
born with an oral cleft deformity between 1936 and 1998 and followed in the Danish Cancer
Registry from 1968 through 1998, a total of 175,863 person-years, the possible association
between cancer and oral clefts was assessed [202]. The expected overall number of all cancers
was 131, but 140 incident cancers were found, corresponding to a standardized incidence ratio
of 1.07 (95%CI, 0.90-1.26). Analyses of the 52 sites for all oral cleft cases and analyses stratified
into three cleft subgroups and two sexes revealed only a few significant associations, one of
which was the increased incidence of primary brain cancer among females, but not males, born
with a cleft palate (SIR = 3.11; 1.14, 6.78).
Finally, medications are often listed as a potential risk factor for brain cancer [203], but there
are almost no data scientifically supporting such a claim. In one case-control study of 163
matched pairs, patients under 15 years of age when diagnosed with astrocytoma between 1980
and 1986 were identified through the tumor registries of eight hospitals in Pennsylvania, New
Jersey, and Delaware [204]. Controls were selected by random digit dialing, and matched to
cases for age, race, and telephone area code and exchange. In this population, maternal anti-
nausea medications significantly increased the risk of childhood astrocytoma [OR = 2.0, p =
0.04], while gestational exposure to marijuana was of borderline significance (OR = 2.8, p =
0.07). Gestational exposures to neurally-active medications, alcohol, and tobacco did not
increase brain cancer risk, consistent with other studies [203]. The association between anti-
emetics and increased brain cancer risk was not identified in another, Swedish study in which
this was assessed [205]. In the Swedish study, no significant changes in risk were noted after
exposure to iron supplementation, anti-emetics, analgesics, antibiotics or any other drug, with
the exception that 10 children with a brain tumor had been exposed to some beta-blocking
agent in utero versus just two children without brain tumor (adjusted OR 5.3, 95%CI 1.2-24.8).
In addition, a tendency towards a protective effect was observed for prenatal exposure to folic
acid (adjusted OR 0.6; 0.3-1.1). Finally, case-control data from M. D. Anderson Cancer Center
and the University of California, San Francisco were pooled to conduct an analysis stratified
by histological subtype of glioma to identify any potentiating effects of inflammation-related
variables and antihistamine use [206]. An association was discovered between long-term
antihistamine use and the increased risk of anaplastic gliomas, especially when the length of
use was considered in conjunction with a history of asthma or allergy: anaplastic cases with
no history of asthma or allergy were 2.94 times more likely than controls to report antihistamine
use lasting 10 years or more; while anaplastic cases with a history of asthma or allergy were
2.34 times more likely. Conversely, anti-inflammatory medication use was protective against
glioblastoma (OR = 0.80; 95%CI: 0.65, 0.99), especially among individuals with no history of
asthma or allergies. No statistically-significant effects of anti-inflammatory drugs or antihist‐
amines were evident for other histological subtypes of glioma.
8. Summary, clinical applications, and directions for future research
Brain cancer is one of the most fear-provoking and lethal of all illnesses, two reasons that
concerns about the potential for increased rates from the use of hand-held electronic devices
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have been raised. To date, however, there is no evidence that brain cancer incidence rates have
increased at all over the same time period that the use of these devices has escalated expo‐
nentially. In the U.S. and U.K., where data are available, brain cancer incidence rates appear
to be stable or declining. Mortality rates also are declining. That being said, there are virtually
no readily-accessible data outside the U.S. and the U.K., and there is some research evidence
that any effects of such devices on brain cancer risk only become significantly and clinically
manifest after years, if not decades of their use. Consequently, it may be too soon to have
detected adverse effects and, if present, to determine the magnitude of such effects on brain
cancer numbers.
Known risk factors for brain cancer are male gender, younger age among pediatric popula‐
tions, and Caucasian race. A family or personal history of cancer, and in particular brain cancer
appears to increase risk as well, as do radiation treatments to the head and neck area. In
addition, a small percentage of brain cancer cases, likely 5 percent or less, occur within the
context of a familial syndrome, the most common of which are neurofibromatosis and tuberous
sclerosis. In such patients, the risk is high for a variety of intracranial and extra-cranial
malignancies, so that continuous vigilance by qualified health care practitioners is paramount.
Unfortunately, research into a variety of suspected brain cancer risk factors has been fraught
with difficulties, given problems accurately evaluating levels of exposure, controlling for
numerous other potentially carcinogenic exposures, and issues like recall and ascertainment
bias. As stated earlier, understanding about the true risk of hand-held devices like cell phones
may not come until they have been in widespread use for several more years, at which point
it may be too late to prevent whatever initial rise in cases results. The same is true for electro‐
magnetic fields from the increasing number of household appliances, especially home
computers that are entering our homes, though the trend has been towards negative-result
studies as methodologies have advanced over the years. As for dietary factors, other than
promoting good diet and moderation in the consumption of cured meats, little more can be
said at this time. And all patients should be advised to exercise caution when partaking in any
occupation, hobby or other activity that places one in regular close contact with chemicals or
ionizing radiation.
Further research clearly is needed to clarify the huge number of yet-unanswered questions,
but this must start with close and international monitoring of brain cancer rates, both overall
and cancer-type specific. In the U.S., the SEER database is a huge advantage; but investigators
need to utilize this database more and publish these results within the medical literature. The
number and completeness of similar databases in other countries this author cannot say; but
again, such databases need to be used for research purposes and resultant findings published
on a regular basis, if changing trends in brain cancer incidence are to be detected early. As for
establishing the magnitude of risk from devices like cell phones, if such risk actually exists,
what are needed are large, prospective, longitudinal studies assessing dose-dependent effects,
since it makes sense that the highest-volume users will be the ones most likely to present
earliest with problems, a contention that already-published results support. Moreover, using
prospective studies will largely counter the problems with recall and ascertainment bias that
has plagued the numerous case-control studies published to date though, admittedly, such
Clinical Management and Evolving Novel Therapeutic Strategies for Patients with Brain Tumors626
studies invariably must be larger and, hence costlier. This being said, it is important to recall
those databases already in existence, like the SEER database and State and provincial cancer
registries. Linking prospectively-acquired, multicenter exposure data with some database like
these would provide a powerful research tool in the fight against brain cancer.
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